News

2

Jul, 2018

An EPIICAL paper has been accepted for publication in the Journal of Acquired Immune Deficiency Syndromes (JAIDS)

 

In this paper, just accepted for publication in JAIDS, we demonstrate that HIV infected children who start ART earlier in life and remain suppressed without blips or treatment failure have the lowest viral reservoir as they mature through childhood. Importantly, this study provides further evidence to support current guidelines that recommend treatment with ART as soon as possible in perinatally HIV infected children. The full text version is available in the Publications section of the EPIICAL website.

READ MORE

29

Jun, 2018

ODYSSEY: recruitment has completed!

 

We are pleased to announce that recruitment to the main trial has now completed. We have recruited slightly more than the total target of 700 participants: 312 recruited into ODYSSEY A (naïve to HIV treatment) and 396 into ODYSSEY B (starting second line HIV treatment).

READ MORE

21

May, 2018

EARTH: first patient has been recruited!

Tags: , , ,

It is with great pleasure that we announce that the first patient in the EARTH study has been recruited. This encouraging news comes to us from the PHRU site in Soweto, South Africa. Now that all sites are open for recruitment, with some patients having already been screened, we are confident we will see more participants in the near future. This is the first of 150 children to be enrolled from one of 5 sites situated in South Africa and Mozambique. The EARTH project, nested within the EPIICAL platform, is a prospective multicentre, low-interventional study of HIV+ perinatally […]

READ MORE

21

May, 2018

The c4c project has been approved

 

We are delighted to announce the launch of the c4c project.
This heralds a new public-private partnership to improve clinical trial infrastructure to facilitate the development of new drugs for children in Europe.

READ MORE